Dr. Haifeng Zhao 赵海丰
Chief Physician, Associate Professor
Department of Hematology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of multiple myeloma, malignant lymphomas, acute leukemia, tumor-related anemia, and tumor-related thrombocytopenia. Emphasizes comprehensive and individualized care using chemotherapy, targeted therapy, and hematopoietic stem cell transplantation.
Dr. Zhao holds an MD and completed postdoctoral training at New Jersey Medical School. A visiting scholar at MD Anderson Cancer Center, Dr. Zhao is a master’s supervisor and a Tier 2 talent in Tianjin’s 131 Innovation Project. Research focuses on epigenetics in lymphoma pathogenesis. Dr. Zhao leads two National Natural Science Foundation projects and has published over 30 papers, including 17 SCI articles as first or corresponding author.
Professional roles
- Reviewer for Autoimmunity
- Reviewer for Platelets
- Reviewer for BMC Veterinary Research
Name order: in Chinese the family name comes first (Zhao Haifeng). Papers usually list the name as Haifeng Zhao or Zhao H.
Selected publications
39 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Exp Med, 2022 (senior author): Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma. PubMed 34427833
- Oncol Lett, 2020 (senior author): Overexpression of microRNA-130a predicts adverse prognosis of primary gastrointestinal diffuse large B-cell lymphoma. PubMed 32831912
- Oncol Lett, 2020 (senior author): miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma. PubMed 32269622
- Biosci Rep, 2019 (first author): Genetic polymorphism and transcriptional regulation of CREBBP gene in patient with diffuse large B-cell lymphoma. PubMed 31366566
- Cancer Cell Int, 2018 (senior author): SIRT1 rs3758391 polymorphism and risk of diffuse large B cell lymphoma in a Chinese population. PubMed 30377410
- Onco Targets Ther, 2016 (first author): Comorbidity as an independent prognostic factor in elderly patients with peripheral T-cell lymphoma. PubMed 27069369
- Oncol Lett, 2015 (first author): Overexpression of DNA methyltransferase 1 as a negative independent prognostic factor in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab. PubMed 26137062
- Autoimmunity, 2014 (first author): Interleukin-18 gene promoter--607 A/C polymorphism and the risk of immune thrombocytopenia. PubMed 24897237
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion